help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tivesten, A.
Right arrow Articles by Isgaard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tivesten, A.
Right arrow Articles by Isgaard, J.
Endocrinology Vol. 141, No. 1 60-66
Copyright © 2000 by The Endocrine Society

ARTICLES

The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction1

Åsa Tivesten, Entela Bollano, Kenneth Caidahl, Vuk Kujacic, Xiang Ying Sun, Thomas Hedner, Åke Hjalmarson, Bengt-Åke Bengtsson and Jörgen Isgaard

Research Center for Endocrinology and Metabolism, the Department of Internal Medicine (Å.T., B.-Å.B., J.I.), Wallenberg Laboratory (E.B., Å.H.), the Department of Clinical Physiology (K.C., V.K.), and the Department of Clinical Pharmacology (X.Y.S., T.H.), Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden

Address all correspondence and requests for reprints to: Jörgen Isgaard, M.D., Ph.D., Research Center for Endocrinology and Metabolism, Gröna Stråket 8, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. E-mail: jorgen.isgaard{at}ss.gu.se

Several studies have shown that GH can enhance cardiac performance in rats after experimental myocardial infarction and in humans with congestive heart failure. In the present study, the hemodynamic effects of hexarelin (Hex), an analog of GH-releasing peptide-6 and a potent GH secretagogue, were compared with the effects of GH. Four weeks after ligation of the left coronary artery male rats were treated sc twice daily with hexarelin [10 µg/kg·day (Hex10) or 100 µg/kg·day (Hex100)], recombinant human GH (2.5 mg/kg·day), or 0.9% NaCl for 2 weeks. Transthoracic echocardiography was performed before and after the treatment period. GH, but not Hex, increased body weight gain. GH and Hex100 decreased total peripheral resistance (P < 0.05) and increased stroke volume (P < 0.05 and P < 0.01, respectively) and stroke volume index (P = 0.06 and P < 0.01, respectively) vs. NaCl. Cardiac output was increased by GH and Hex100 (P < 0.05), and cardiac index was increased by Hex100 with a borderline significance for GH (P = 0.06). In conclusion, Hex improves cardiac function and decreases peripheral resistance to a similar extent as exogenous GH in rats postmyocardial infarction. The mechanisms of these effects are unclear; they could be mediated by GH or a direct effect of Hex on the cardiovascular system.




This article has been cited by other articles:


Home page
 J EndocrinolHome page
T. Chen, Z. Tang, A. Yan, W. Li, and H. Lin
Molecular cloning and mRNA expression analysis of two GH secretagogue receptor transcripts in orange-spotted grouper (Epinephelus coioides)
J. Endocrinol., November 1, 2008; 199(2): 253 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Baessler, M. Fischer, B. Mayer, M. Koehler, S. Wiedmann, K. Stark, A. Doering, J. Erdmann, G. Riegger, H. Schunkert, et al.
Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease
Hum. Mol. Genet., April 15, 2007; 16(8): 887 - 899.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
A Tivesten, E Bollano, H C Nystrom, C Alexanderson, G Bergstrom, and A Holmang
Cardiac concentric remodelling induced by non-aromatizable (dihydro-)testosterone is antagonized by oestradiol in ovariectomized rats.
J. Endocrinol., June 1, 2006; 189(3): 485 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Marleau, M. Mulumba, D. Lamontagne, and H. Ong
Cardiac and peripheral actions of growth hormone and its releasing peptides: Relevance for the treatment of cardiomyopathies
Cardiovasc Res, January 1, 2006; 69(1): 26 - 35.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. G. Brywe, A.-L. Leverin, M. Gustavsson, C. Mallard, R. Granata, S. Destefanis, M. Volante, H. Hagberg, E. Ghigo, and J. Isgaard
Growth Hormone-Releasing Peptide Hexarelin Reduces Neonatal Brain Injury and Alters Akt/Glycogen Synthase Kinase-3{beta} Phosphorylation
Endocrinology, November 1, 2005; 146(11): 4665 - 4672.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
Endocr. Rev., June 1, 2004; 25(3): 426 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. A Lucchesi
Growth hormone-releasing peptides and the heart: secretagogues or cardioprotectors?
Cardiovasc Res, January 1, 2004; 61(1): 7 - 8.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
X.-B. Xu, J.-M. Cao, J.-J. Pang, R.-K. Xu, C. Ni, W.-L. Zhu, K. Asotra, M.-C. Chen, and C. Chen
The Positive Inotropic and Calcium-Mobilizing Effects of Growth Hormone-Releasing Peptides on Rat Heart
Endocrinology, November 1, 2003; 144(11): 5050 - 5057.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y.-T. Shen, J. J. Lynch, R. J. Hargreaves, and R. J. Gould
A Growth Hormone Secretagogue Prevents Ischemic-Induced Mortality Independently of the Growth Hormone Pathway in Dogs with Chronic Dilated Cardiomyopathy
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 815 - 820.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
G. Baldanzi, N. Filigheddu, S. Cutrupi, F. Catapano, S. Bonissoni, A. Fubini, D. Malan, G. Baj, R. Granata, F. Broglio, et al.
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT
J. Cell Biol., December 23, 2002; 159(6): 1029 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
E. Bollano, C.-H. Bergh, C. Kjellstrom, E. Omerovic, V. Kujacic, K. Caidahl, B.-A. Bengtsson, F. Waagstein, and J. Isgaard
Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats
Eur J Heart Fail, December 1, 2001; 3(6): 651 - 660.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Y. Bowers
Unnatural Growth Hormone-Releasing Peptide Begets Natural Ghrelin
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1464 - 1469.
[Full Text]

Home page
 EndocrinologyHome page
F. Weekers, E. Van Herck, J. Isgaard, and G. Van den Berghe
Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model
Endocrinology, November 1, 2000; 141(11): 3993 - 3999.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Papotti, C. Ghè, P. Cassoni, F. Catapano, R. Deghenghi, E. Ghigo, and G. Muccioli
Growth Hormone Secretagogue Binding Sites in Peripheral Human Tissues
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3803 - 3807.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society